In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

The following is a summary of “Association between incretin-based drugs and risk of cholangiocarcinoma among patients with ...

The following is a summary of “Effects of Novel Antidiabetic Agents on Contrast-Associated Acute Kidney Injury in Diabetic Patients Undergoing Percutaneous Coronary Intervention,” published in the ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...

GoodRx CEO Wendy Barnes outlined the company's priorities at the 2025 JP Morgan Healthcare Conference in San Francisco.

The CDMO's growth strategy, capital deployment approach, and work with AI, among other things, have been key to its 2024 performance.

Positive results in a recent animal study strongly supports first-ever human investigation for DehydraTECH-liraglutide in an oral capsule format KELOWNA, BC / ACCESSWIRE / January 15, 2025 / Lexaria B ...

Hanmi Pharmaceutical Senior Vice President Choi In-young, head of the R&D center, speaks to Korean media outlets at a press ...

For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescription is associated with reductions in risk-adjusted ...

BMI falls short as a way to measure obesity. Doctors need to also determine whether body fat harms a person's health.

A dietetics professor explains who should and should not embrace the latest weight-loss drugs. Holiday weight gain hits home ...